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background: Left atrial appendage (LAA) occlusion is proposed to reduce the risk of stroke in atrial fibrillation patients. The aim of this study was 
to evaluate safety and healing response of the WaveCrestTM (Coherex Medical, Salt Lake City, UT) LAA occluder in a canine model.
Methods: The occluder was deployed in the LAA in 12 dogs via transseptal puncture, confirming position and ostial occlusion by transesophageal 
echocardiography (TEE) and fluoroscopy. Histopathology was assessed 30 days (n=6) or 180 days (n=6) after implantation.
results: The mean LAA ostial diameter was 17.9±2.9mm. The LAA occluders were successfully implanted in all 12 animals without pericardial 
effusion or other complications. Post-implant TEE showed devices in the intended position successfully occluding the LAA ostia (sealing grade = 
4.75±0.5). Histopathology showed adequate deployment and circumferential occlusion (Fig a). The endocardial surface of the occluder was fully 
covered by neointima at 30 days and completely endothelialized by 180 days. The tissue plug isolated behind the occluder was partially organized 
into mature fibrous connective tissue by 180 days (Fig b). No adverse histology findings were noted in the myocardia, mitral valves, kidneys or brains.
conclusions: Percutaneous delivery of the WaveCrestTM LAA occluder shows feasibility and safety in a canine model. All devices achieved 
occlusion of the LAA without any adverse events, with complete endothelialization and fibrous organization by 180 days.
